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Abstract L-Arginine, the substrate of nitric oxide (NO)
synthases (NOSs), is found in the mammalian organism at
concentrations by far exceeding KM values of these enzymes.
Therefore, additional L-arginine should not enhance NO forma-
tion. In vivo, however, increasing L-arginine concentration in
plasma has been shown repeatedly to increase NO production.
This phenomenon has been named the L-arginine paradox; it has
found no satisfactory explanation so far. In the present work,
evidence for the hypothesis that the endogenous NOS inhibitors
methylarginines, asymmetric dimethylarginine being the most
powerful (IC50 1.5 WM), are responsible for the L-arginine
paradox is presented. ß 2000 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
L-Arginine is the exclusive physiological substrate for vari-
ous isoforms of the nitric oxide (NO) synthases (NOSs) family
(EC 1.14.13.39) which catalyzes the oxidation of L-arginine to
NO and L-citrulline [1]. At least three isozymes have been
identi¢ed for NO production from L-arginine [2]. These iso-
zymes have been classi¢ed as isoform I in neuronal (nNOS)
and epithelial cells, isoform II in cytokine-induced cells
(iNOS) and isoform III in endothelial cells (eNOS). nNOS
and eNOS are dependent on and iNOS is independent of
Ca2 [2]. Half-saturating L-arginine concentrations (KM)
were reported as 1.4^2.2 WM for nNOS, 2.8^32.3 WM for
iNOS and 2.9 WM for eNOS [2]. L-Arginine is supplied to cells
by a y transport system speci¢c for cationic amino acids [3].
Freshly isolated endothelial cells have been found to contain
up to 2 mM L-arginine [4]. Considering this and a KM of 2.9
WM for L-arginine for eNOS [2], this enzyme should be satu-
rated in endothelial cells. It is surprising that intravenous (i.v.)
or oral supplementation of L-arginine in vivo in humans aug-
ments endothelial NO production [5^18]. Supplementation of
L-arginine to hypercholesterolemic animals [5,6] and humans
[7,8], in which endothelium-dependent vasodilatation is im-
paired, was found to improve endothelial dysfunction by in-
creasing NO production [5^8]. Also, supplementation of L-ar-
ginine. This phenomenon, generally known as the L-arginine
paradox, has found no satisfactory explanation so far. We
here present evidence that concentrations of endogenous
NOS inhibitors in vivo provide a satisfactory explanation
for this phenomenon.
2. Proposal
The L-arginine paradox may be solved by proposing that
NOS isoforms are potently inhibited in vivo and in vitro in
intact cells by endogenously produced compounds. Mecha-
nism of inhibition, inhibitor potency and intracellular concen-
trations of inhibitors, L-arginine and cofactors including Ca2
regulate NOS activity and consequently NO production in
cells capable of synthesizing NOS. Under physiological con-
ditions, the enzyme activities of NOS isoforms are lowered to
a fraction of their maximum activities (Vmax) although the
enzymes are exposed to concentrations of L-arginine which
theoretically should allow the enzymes to operate at the
Vmax values of the uninhibited enzymes. Under pathological
conditions, increased intracellular concentrations of the inhib-
itors cause additional decreases of the activity of the NOS
enzymes which result in NO formation rates below the phys-
iological levels. Under physiological and pathophysiological
conditions, i.v. or oral administration of L-arginine causes
an increase in circulatingL-arginine concentrations which leads
to an increase in intracellular L-arginine concentrations and
exchange of intracellular inhibitors against extracellular L-ar-
ginine via the y transport system in NOS producing cells.
Antagonization of L-arginine with competitive inhibitors and
decrease of intracellular concentrations of competitive and
non-competitive inhibitors by extracellular L-arginine cause
an increase in NOS activity and augmentation of NO produc-
tion. These e¡ects are dependent on the administered amount
of L-arginine and last as long as circulating L-arginine concen-
trations are above the L-arginine concentrations before admin-
istration.
3. Evidence supporting this hypothesis
1. Presently, two endogenous potent inhibitors of NOS-cat-
alyzed formation of NO from L-arginine are known, i.e. the
methylated L-arginines, NG,NG-dimethyl-L-arginine (asymmet-
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ric dimethylarginine, ADMA) and NG-methyl-L-arginine
(NMA) [18^27]. Plasma concentrations of ADMA in healthy
humans are in the range of 0.5^1.0 WM [23^27]. ADMA and
NMA occur in endothelial cells of rabbits at a concentration
of 5 WM each [28].
2. ADMA and NMA are potent inhibitors of various NOS
isoforms (Fig. 1) [19,29^34]. ADMA and NMA inhibit NO
synthesis with comparable potencies in vitro and in vivo, in
blood vessels and macrophages, in animals and in man [19].
ADMA is a non-competitive inhibitor (Ki 0.4 WM; Kii 1.6
WM; IC50 1.5 WM) of an isolated nNOS (Fig. 1) [34]. The
IC50 for ADMA in rat brain homogenates is 2 WM [35].
NMA is not simply a competitive inhibitor of several NOS
isoforms (Ki 3.9, 0.65 and 0.7 WM for iNOS, nNOS and
eNOS, respectively [36]), but it also induces time-dependent
inactivation of macrophage and brain NOS [29^36]. ADMA is
a more potent inhibitor of nNOS than NMA (Fig. 1) [33].
3. In various pathological conditions associated with endo-
thelial dysfunction such as essential hypertension, atheroscle-
rosis and hypercholesterolemia, ADMA plasma concentra-
tions are elevated while urinary excretion of the NO
metabolites nitrite and nitrate (Fig. 2) and of cGMP, the
second messenger of NO, are reduced both in animals and
in humans; under these conditions, the L-arginine concentra-
tion is almost normal [24,26,27,37^39].
4. I.v. or oral administration of L-arginine to healthy and ill
humans as well as to animals results in endothelium-depen-
dent vasodilatation, in increase of plasma nitrite concentra-
tion and enhanced urinary excretion of nitrate (Fig. 2) and
cGMP [9^11,14]. These e¡ects correlate with plasma L-argi-
nine concentrations and last as long as the L-arginine plasma
concentration is several fold higher than the respective basal
level [9,10]. Signi¢cant endothelium-dependent, L-arginine-in-
duced vasodilation, NO and cGMP production occurs after
i.v. infusion of 30 g of L-arginine in healthy humans that
results in plasma L-arginine concentrations 10^80-fold higher
than the basal levels (Fig. 2) [9^11,14]. The extent of conver-
sion of L-[guanidino-15N2]arginine to [15N]nitrate in cholester-
ol-fed rabbits strongly and inversely correlates (r = 0.77,
P6 0.05) with ADMA plasma concentrations [40]. The results
from a meta-analysis of currently available literature data on
NO production in dependence on plasma L-arginine to
AMDA ratio in humans and animals show a good correlation
between these parameters (Fig. 2) and strongly support our
hypothesis.
5. ADMA, symmetric dimethylarginine (SDMA) and NMA
compete with L-arginine transport mediated by the inducible
human y transport system hCAT-2B [3]. The inhibition of
hCAT-2B-mediated L-arginine transport by SDMA is reversed
by excess of L-arginine. Thus, the inhibitory e¡ect of these
methylarginines on NOS isozymes in various intact cells
may be a¡ected by the extracellular concentration of
ADMA, SDMA, NMA and L-arginine. Increased NO produc-
tion seen in vivo after administration of L-arginine at high
doses could result from an exchange of intracellular inhibitors
against circulating L-arginine.
4. Conclusions and future prospects
The evidence cited above can provide a satisfactory explan-
ation for the L-arginine paradox by assigning ADMA, the
most powerful endogenous inhibitor of NOS, a central role.
However, few data exist on the transport of ADMA in and
out of NO producing cells and additional work is required to
fully characterize its intracellular concentrations. Further, the
e¡ect of L-arginine and ADMA on NOS cofactor requirement
has not been evaluated. Data from such investigations would
help to prove the present hypothesis.
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Fig. 1. Simulation of nNOS activity for competitive (by NMA; Ki
0.6 WM [32]) and non-competitive (by ADMA; Ki 0.4 WM; Kii 1.6
WM [33,34]) mechanisms-based inhibition at inhibitor concentrations
of 0, 1 and 2 WM. KM was set to 3.1 WM [33]. Vmax = 0.204 Wmol
[15N]nitrite per min per mg nNOS was set to 100% for the non-in-
hibited enzyme [33]. L-Arginine concentration was varied as indi-
cated.
Fig. 2. Meta-analysis between NO production in vivo in humans
and animals and logarithmic (log) plasma L-arginine to ADMA con-
centration ratio. Data were involved in this meta-analysis from stud-
ies described in [9,10,13,24,26,27,38,39]. Symbols are accompanied
with the respective reference numbers. NO production of 100% is
de¢ned as the plasma nitrite concentration or urinary nitrate excre-
tion in the respective control group with a log ([L-Arg]/[ADMA])
value of about 1.9. NO production values above 100% and below
100% indicate increased and decreased NO production, respectively,
with respect to that of the control group.
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